EASME

A French startup created by CNRS researchers at the Physics and Mechanics of Heterogeneous Media (PMMH) Laboratory in Paris, Aenitis Technologies develops bioprocessing medical devices that use acoustophoresis to separate, manipulate and filter biological elements, with a focus on cell therapy manufacturing such as cell sorting, washing and isolation for cell therapy units and blood banks. The company aims to provide acoustic preparation solutions to streamline cell therapies and advance public health, pursuing leadership in acoustophoresis-based separation.

Vital Beats develops a medical platform for remote care of heart patients with pacemakers. The platform combines participatory design, data science, and machine learning to monitor cardiac devices remotely and predict health conditions.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

InterAx Biotech Ltd is a biotechnology company based in Villigen, Switzerland, focused on developing a platform for the discovery of functionally selective drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 2016, the company integrates bioanalytical methods and computational pharmacology to assist in drug candidate design and selection. Its innovative platform combines high-throughput biochemical screening with artificial intelligence and mathematical modeling of cell signaling, facilitating the identification and optimization of drug candidates for various diseases, including those associated with orphan GPCRs. Through its advanced approach, InterAx Biotech aims to improve drug efficacy while reducing side effects, contributing to the healthcare industry's efforts to discover safer and more effective treatments.

Nuada is a company based in Braga, Portugal, specializing in the development of innovative systems designed to improve hand function. Its products cater to various sectors, including healthcare, sports, and professional activities. Nuada's solutions are characterized by their lightweight, compact, and non-intrusive design, employing thin, breathable, and flexible smart textiles that can be customized by users. The company aims to create a unique enhancement technology that serves as an essential wearable, designed for everyday use while being comfortable enough for individuals to forget they are wearing it.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Neuro Device Group S.A. is a Polish med-tech company, established in 2008 and based in Warsaw, specializing in the development and manufacturing of medical devices aimed at addressing neurological disorders. The company's product lineup includes Neuro Device Camri, a diagnostic recording camera for MRI scanners; Neuro Device Scent, which measures neuronal reactions to scents; and Neuro Device Tacti, a stimulator used in preoperative fMRI diagnostics to localize brain sensomotoric areas. In addition to its proprietary devices, Neuro Device Group also distributes a range of high-quality neurological products and medical devices from leading global manufacturers, encompassing areas such as eye tracking, rehabilitation, virtual reality, and fMRI. The company's ongoing mission is to enhance neurological research and improve patient outcomes through innovative technologies.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

D-Tech System is a new generation of disinfection solution providing outstanding performance The D-Tech System is a powerful and ecological disinfection solution, including equipment and environmentally friendly biocidal materials, that eliminates and prevents bacteria growth and has a long lasting disinfection impact. D-Tech caters to demanding industries that require cost effective and modern disinfection procedures in their production facilities and transportation vessels, including food, aquaculture and logistics industries.

Elypta develops a liquid biopsy platform using metabolism-based biomarkers and artificial intelligence. Its platform measures glycosaminoglycan metabolites in blood and urine, aiming to enable earlier detection and monitoring of various cancer types.

Double Bond Pharmaceutical is a pharmaceutical company that develops and commercializes innovative first-in-class therapies for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders. It aims to provide patients and markets with safer, more effective products in areas where medical needs remain unmet.

Founded in Sweden in 2011, Brain Stimulation specializes in innovative neurological rehabilitation. They leverage brain plasticity research to develop effective, individualized care for stroke, dementia, traumatic brain injuries, and other degenerative brain diseases.

Toleranzia is a Swedish biotechnology company developing drugs that harness the immune system's power to treat rare autoimmune diseases. Its pipeline includes TOL2 for myasthenia gravis and TOL3 for ANCA vasculitis, both targeting disease-specific proteins.

Healthplus.ai leverages electronic health record data to predict post-surgical complications, empowering healthcare professionals to proactively manage patient care, reduce complication impacts, improve outcomes, and lower costs.

PYRATES Established in 2014 and run by Y-generation women, PYRATES smart fabrics provides the solution to protecting their bodies from the polluted, aggressive external elements that surround us through its PYRATEX®: a textile, health-benefitting armour that protects and cares for the wearer’s body.

Founded in 2017, Dufour Aerospace is a Swiss aviation company specializing in aerospace engineering. It initially developed aerobatic aircraft but has since shifted focus to creating next-generation electric aircraft for sustainable cargo transportation and public safety missions.

Hystrix Medical operates a digital marketplace designed to streamline the procurement process for medical devices and repeat purchase products within hospitals. The platform connects healthcare organizations with suppliers, significantly reducing the typical 4-6 month contracting timeline by providing a comprehensive one-stop shop that establishes a transparent market price landscape. It focuses on medical products that require minimal explanation for transaction, aiming to enhance the efficiency of hospital personnel and suppliers. By facilitating easier and more effective procurement and sales, Hystrix Medical has demonstrated an average total cost savings of 40% for its users, making it a valuable resource in the healthcare supply chain.

Mimetis Biomaterials SL is a Spanish company founded in 2013, specializing in the design and manufacture of biomimetic bone graft substitutes for medical applications in dental, craniomaxillofacial, and orthopedic sectors. The company focuses on creating synthetic bone grafting solutions that mimic the properties of natural bone, thereby facilitating the colonization of grafts by bone cells and improving outcomes in complex cases. Mimetis offers a range of products, including biomaterial granules and patient-specific 3D-printed grafts, to address various bone defect filling needs. In addition to its product offerings, the company provides consulting, original equipment manufacturing, and co-development services to clinicians. Mimetis Biomaterials was previously known as Subtilis Biomaterials S.L. until its name change in January 2016 and is headquartered in Barcelona, Spain.

Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Lucine is a company focused on improving patient health, primarily targeting pain management. It develops a mobile health application that offers a digital therapeutic solution designed to relieve pain within five minutes through analgesic neurostimulation. The application employs advanced algorithms to measure and analyze pain by utilizing facial, vocal, and postural recognition. This technology allows for personalized treatment, as it instantly adapts to each patient's specific needs. The application provides a variety of techniques to alleviate pain symptoms, including exercises, relaxation methods, art therapy, and meditation, empowering patients with chronic pain to manage their conditions effectively from home.

AmyPore is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, specifically Alzheimer's and Parkinson's. Its lead product, AmyP53, is a chimeric peptide created using artificial intelligence applied to molecular neuroscience. This groundbreaking drug targets a common mechanism underlying both diseases by blocking the formation of neurotoxic structures, specifically oligomers of amyloid proteins, which are responsible for their progression. AmyP53 represents a novel therapeutic class, being the first molecule capable of addressing the shared pathophysiological aspects of Alzheimer's and Parkinson's diseases, thus providing new hope for patients affected by these conditions.

CreatSens develops a platform that provides paper-based creatinine and potassium potentiometric sensors solutions to the healthcare industry. It helps healthcare professionals to better manage the information that can be generated in primary care centers, doctor’s office or patient’s homes. CreatSens platform aims to improve the well-being of people by allowing the monitoring of relevant biochemical parameters of blood out of the lab. The biochemical and physical information will be integrated into a technological platform allowing an accurate prediction, early detection and better prevention of acute conditions from home. The company was founded in 2017 and is headquartered in Tarragona, Catalonia, Spain.

EarWays Medical Ltd. is an innovative company focused on developing effective ear-care solutions aimed at improving the well-being of both children and adults. The company specializes in a medical device designed for the removal of earwax, utilizing a clinically proven and patented technology that features a flexible coated helical tip for easy navigation within the ear canal. This device facilitates cerumen extraction, management, and addresses earwax impaction, which can lead to temporary hearing loss. EarWays Medical offers user-friendly ear care products that are suited for both clinical environments and home use. The company is supported by a team of experts in bioengineering, medical devices, ear surgery, and hearing rehabilitation, positioning it to significantly enhance the accessibility and effectiveness of ear care solutions.

Kheiron Medical Technologies is a London-based medical technology company that develops Mia, an AI-powered mammography screening tool designed to help radiologists detect breast cancer. The system combines deep learning with radiology insights to improve detection efficiency, consistency, and accuracy across imaging workflows. Incorporated in 2016 and formerly known as Maesterai, the company maintains an international presence with offices in London, San Francisco, Budapest, and Amsterdam, aiming to advance precision radiology and improve outcomes for cancer patients.

Arteries Studio Kft. is a Budapest-based company established in 2003 that specializes in the development of web and mobile applications. The firm offers a range of services, including the creation of websites, webshops, and online software, as well as Odoo ERP development. In mobile application development, Arteries Studio focuses on platforms such as iOS and Android, and also extends its expertise to wearable technology like smartwatches and Google Glass. Additionally, the company provides graphic design services, encompassing corporate identity, desktop publishing design, and 3D design and modeling. Arteries Studio has built a strong reputation for agile project management in IT development and has collaborated with notable clients including Unilever, KPMG, and NATO. In recent years, the company has concentrated on business applications and health-related web and mobile solutions, often integrating external hardware and smart sensors through partnerships with hardware manufacturers.

Virtual Bodyworks is a company committed to improving lives by harnessing the power of scientifically-proven breakthrough technology. Their company specialises in immersive virtual reality focused on medical and psychological rehabilitation. Founded by scientists world renowned for their work in VR, we offer products that integrate a unique combination of computer science engineering, neuroscience and psychology.

Biom'Up designs, develops and manufactures absorbable medical devices based on collagen technology for biosurgery. The company offers Hemoblast products for hemostasis and related laparoscopic applicators, and Hemosnow solutions for guided tissue regeneration, serving orthopedics, spine, cardiac, general, maxillofacial, dental and other surgical specialties. It markets its products in Europe and the United States. Biom'Up was founded in 2005 and is based in Saint-Priest, France.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Cellcomb AB is a manufacturer based in Säffle, Sweden, specializing in environmentally friendly disposable laminate products. Established in 1980, the company focuses on producing items that meet high standards of hygiene, comfort, and safety, particularly for the food and healthcare industries. Its product range includes homeaway towels and bedding, food absorbers such as CELLSORB - ECO, CELLSORB - ACTIVE, and CELLSORB - MAX, as well as various hygiene and healthcare items like surgical laminates, mattress covers, and underlays. Cellcomb is recognized as one of Europe’s leading manufacturers in its sector, emphasizing flexibility, expertise, and environmental responsibility in its operations.

Surgitate is a Turkish startup founded by Ozge Akbulut (PhD in Materials Engineering) and Barkın Eldem (MD, Thoracic Surgeon). They manufacture synthetic models for medical professionals and students to practice surgical procedures realistically. Their product range includes skin, breast, and vascular models designed to mimic incision, dissection, and suturing. Surgitate benefits from investments by Farplas, a leading automotive parts manufacturer, which aids in mass production processes, and Inovent, Turkey's first tech commercialization accelerator, facilitating connections with potential investors and customers.

Cogvis specializes in computer vision, machine learning, and 3D data analytics to enhance patient safety and caregiver productivity. Founded in 2007, it provides a privacy-protecting AI-based system that monitors patients autonomously, preventing falls and other critical incidents while reducing administrative workload for nurses by up to 30%.

ODI Medical is a developer of advanced medical technology focused on the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's innovative devices streamline the collection of microvascular data, facilitating a variety of clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, early detection of evolving sepsis, and monitoring chronic wounds. Additionally, ODI Medical's technology supports mass screening for infectious conditions such as Ebola, bird flu, and epidemic meningitis. By utilizing non-invasive methods, the company enables medical researchers to enhance patient therapy through a better understanding of microcirculation.

ABLE Human Motion is a Barcelona-based medical device company founded in 2018. It specializes in developing robotic exoskeletons, with its flagship product being the ABLE Exoskeleton. This wearable technology actively assists paraplegic individuals to stand up, walk, and sit down, aiming to enhance rehabilitation efficiency for clinicians and empower users with greater mobility and independence.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

Yakna develops neurorehabilitation applications and hardware professional education popularization of science.

Mecwins develops nanotechnological platforms for sensitive immunoassays, focusing on applications in oncology, cardiovascular disease, and infectious diseases. Their technology improves healthcare outcomes for at-risk populations.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

Vetherapy Corp., established in 2015 and headquartered in San Francisco, specializes in veterinary regenerative medicine and tissue engineering. The company produces stem cell therapy products for cats, dogs, and horses, focusing on accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy's offerings include stem cell and platelet-rich plasma (PRP) banking services, ensuring veterinarians have access to safe and efficient products for various animal health conditions.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

Espansione Group is a medical technology company specializing in the development and distribution of innovative, non-invasive devices for ophthalmology. Their product portfolio includes proprietary photobiomodulation devices, light therapy systems using red, blue, and ultraviolet light, and diagnostic tools for eye screening. These solutions are designed to enhance patient outcomes by leveraging advanced, science-driven therapies, primarily serving the ophthalmology field.

PlatoScience ApS is a Copenhagen-based company founded in 2015 that specializes in neurostimulation technology. It manufactures the PlatoWork headset, a plug-and-play device designed for transcranial direct current stimulation (tDCS). This non-invasive technology modulates neuronal activity by applying a low-intensity current to the scalp, allowing users to enter specific mindsets conducive to task completion. The company aims to make neurostimulation accessible and easy to use for everyone, facilitating improved mental health and enhanced cognitive performance. By providing a wearable device that sends small electronic signals to the brain, PlatoScience seeks to support users in achieving deep focus and effectively performing various tasks.

Minnemera, established in 2017 and based in Stockholm, Sweden, specializes in developing digital cognitive screening tools. These tools automatically compare an individual's test results with normative data and their own baseline values to detect abnormalities, aiding in early detection of neurological conditions.

Evidence-Based Behavior (eB2) is a company that develops healthcare solutions for psychiatric patients using Artificial Intelligence and mobile technologies.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

ImmuneBiotech AB, established in Lund, Sweden in 2013, specializes in the research and development of novel microbiome therapeutics. The company focuses on probiotic lactic acid bacteria and synbiotic formulations that target the gut microbiota and the immune system, aiming to prevent and treat autoimmune and chronic inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.

Biel Glasses, SL is a company based in Barcelona, Spain, established in 2017, that specializes in the development and sale of electronic smart glasses aimed at enhancing mobility and personal autonomy for individuals with low vision. The innovative glasses integrate 3D vision and artificial intelligence algorithms to detect obstacles, changes in terrain, and street crossings, adapting to varying light conditions. Additionally, they feature zoom and image enhancement capabilities, providing a comprehensive solution that empowers users to navigate their environments safely and independently, ultimately improving their quality of life.

Inflection Biosciences Ltd. is a drug development company based in Dublin, Ireland, specializing in the discovery and development of small molecule therapeutics aimed at treating cancer. Founded in 2012, the company focuses on identifying promising early-stage cancer research from academic institutions and other organizations worldwide. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors, which are currently in preclinical development. Inflection Biosciences is committed to advancing these programs through preclinical and early clinical stages, with the intention of partnering with larger pharmaceutical companies for subsequent development and commercialization. The leadership team, comprising individuals with over 60 years of industry experience, leverages a global network of potential partners and service providers to enhance its research and development efforts.

Yetitablet is the most intuitive, versatile and high-performance giant tablet. What makes it special is its open Android OS, a high-performance hardware and curated applications for different industries like healthcare, education, construction, business and tourism. With the Yetitablet they enable their customers to learn, play, communicate and collaborate more efficiently. For more info, visit www.yetitablet.com

Deneb Medical develops a laser-based robotic surgery system and a robotic platform for use in neurosurgery, craniofacial and head and neck surgery, urology, and general surgery. The system uses optical and photonic techniques for tissue ablation and includes three-dimensional visualization, augmented reality guidance, and robotic assistance to enable more accurate, efficient, and minimally invasive procedures, with the goal of improving patient outcomes.

Allergy Data Laboratories continues to manage and support the Allergome project.

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

Scandinavian ChemoTech AB is a clinical development company headquartered in Lund, Sweden. It specializes in cancer care and pain management solutions, primarily through its innovative product, IQWave. This electroporation device uses short electric pulses in conjunction with localized or intravenous chemotherapy to treat various cancers, including head and neck squamous cell carcinoma, malignant melanoma, and breast adenocarcinoma, among others. The company's founders bring extensive experience in surgical oncology and clinical research, driving its commitment to advancing cancer treatment through genuine research and clinical trials. ChemoTech markets its products via distribution channels and a network of opinion leaders across regions such as South East Asia, India, and the Philippines. Established in 2013, the company continues to focus on developing effective therapies for cancer patients.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Stokhos B.V., based in Amsterdam, Netherlands, develops software aimed at optimizing the deployment of emergency vehicles, particularly ambulances. Initially conceived as a scientific mathematical project named REPRO, the company's flagship product, known as seconds, utilizes advanced algorithms to provide real-time coverage advice to emergency dispatch centers. By analyzing factors such as population density, historical incident data, and road networks, Stokhos's platform enables dispatchers to determine the optimal placement of ambulances, ensuring that they can respond swiftly to emergencies within required timeframes. The team at Stokhos is deeply committed to enhancing public safety and has a strong connection to the medical emergency sector, with all members holding valid first aid certifications.

ThermoSiv Technologies develops advanced heating solutions, including ThermoFabric products, to enhance energy efficiency, safety, and health. The company offers smart heating fabrics that enable safe, healthy far-infrared therapy heating, using carbon-based conductive materials to provide uniform warmth and durability. The fabrics are designed for eco-friendly operation and aim to reduce energy consumption in colder periods by delivering efficient, targeted heat.

BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

Magentiq Eye Ltd., established in 2014, specializes in developing AI-driven medical devices for endoscopic procedures. Its flagship product is the Automatic Polyp Detection System (APDS), which uses computer vision and deep learning to assist doctors in real-time colonoscopy examinations, aiming to reduce polyp miss-rates and improve patient outcomes.

300K Solutions is a biotechnology company specializing in the development of innovative products for the storage and shipment of biological samples at room temperature. Its stabilization technology ensures secure preservation, optimizes storage space, and minimizes sample loss.

TargImmune Therapeutics is a Swiss biotech company specializing in targeted onco-immunotherapy drug development. Its core technology, CTPIC, employs a non-viral vector to target and destroy cancer cells expressing specific receptors while stimulating an immune response.

TransCure BioServices SAS is a biotechnology company based in Archamps, France, founded in 2012. The company specializes in vivo pharmacology preclinical services and offers unique research and development platforms, including its Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These innovative models are designed to enhance the drug profiling and development process for pharmaceutical companies, biotech firms, and academic researchers focusing on immuno-related diseases and anti-HIV/AIDS therapies. By providing access to its specialized platforms as fee-for-service offerings, TransCure BioServices enables clients to efficiently generate and characterize humanized mouse models that deliver predictive insights into human drug responses. This capability helps accelerate the development and commercialization of new therapies, ultimately allowing clients to bring effective treatments to market more quickly and cost-effectively.

Nasal is a technology-focused company that specializes in developing automated medical devices for the healthcare sector. It aims to enhance professional practices by providing tools that offer detailed insights into the structure and behavior of the nasal cavity. Through its innovative solutions, Nasal seeks to advance medical simulation technology, thereby assisting and training healthcare professionals. The company's efforts are geared towards improving the quality of care for patients and supporting the ongoing development of medical expertise.

CardiacSense Ltd., founded in 2012 and based in Caesarea, Israel, develops innovative medical wearable devices aimed at monitoring heart arrhythmias and other critical health metrics. The company's FDA and CE certified medical watches and wristbands provide continuous, long-term, ambulatory, and non-invasive monitoring of vital functions, including heart rate, pulse rate, respiratory rate, core temperature, oxygen saturation, and blood pressure. Utilizing advanced PPG technology, CardiacSense's devices enable accurate real-time diagnostics for various medical conditions such as atrial fibrillation, hypertension, chronic obstructive pulmonary disease, heart failure, sleep apnea, and infections like COVID-19. By focusing on the prevention and early detection of cardiac events, CardiacSense aims to enhance healthcare delivery and improve patient outcomes.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Vulcur Medtech is a medical device development company based in Vanløse, Denmark, established in 2018. The company specializes in wound healing through its innovative VulCur MedTech laser technology. This device is designed to target and eliminate biofilm-producing bacteria in chronic wounds by using laser pulses that penetrate tissue, effectively ablating bacteria while preserving human cells. By facilitating the healing of otherwise untreatable wounds, Vulcur Medtech's approach not only accelerates the healing process but also enhances patients' quality of life.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

Algalif supplies astaxanthin products from microalgae, including ingredients and finished formulations. They help solve the nutritional needs of current and future generations through the development and delivery of sustainable microalgae ingredients. They also commercialize a range of immune-health ingredients, for use in food, beverages, nutraceuticals, sports nutrition, and personal care products.

Nateo Healthcare is a Toulouse, France-based medical technology company that designs, develops, and manufactures connected devices and software for obstetrics and gynecology. Founded by obstetricians, gynecologists and medical technology specialists, the company focuses on portable fetal monitoring solutions, including compact mobile fetal heart and uterine activity monitoring systems, and remote patient monitoring for maternity care. Its products enable continuous fetal heart rate and uterine activity assessment, support telemonitoring for home use or hospital settings, and aim to optimize bed utilization in maternity wards while enhancing patient well-being through more flexible care. By integrating wireless connections and real-time data, Nateo Healthcare seeks to provide clinicians with mobile, connected CTG monitoring capabilities and to expand access to monitoring in hospitals and at home.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

Pre Diagnostics is a Norwegian biomarker diagnostics company focused on the early detection of neurodegenerative diseases, especially Alzheimer’s disease. It develops blood-based in vitro diagnostic tests that capture disease-specific systemic responses, including intracellular analysis of monocytes to assess beta-amyloid clearance, with the aim of identifying disease onset before symptoms, improving patient stratification, and supporting precision medicine through laboratory services that back the diagnostic workflow.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

ZygoFix is a medical device company specializing in spine technology. It has developed an innovative three-dimensional-printed implant designed to lock the facet joint of the lumbar spine. This device leverages the anatomy of the spine to provide stability, eliminating the need for traditional external screw-based bridges and reducing the reliance on pedicle screws. By doing so, ZygoFix aims to minimize the risks associated with improper screw placement, thereby enhancing safety in spinal surgeries. The company's focus on advancing spinal stability reflects its commitment to improving patient outcomes in the medical field.

VisionHealth GmbH is a healthcare software company based in Munich, Germany, founded in 2017. It specializes in developing digital solutions for patients with chronic respiratory diseases, such as asthma and COPD. The company's primary product, Kata, is an artificial intelligence and machine learning-based application that connects respiratory patients with healthcare professionals. Kata enhances inhalation therapy by training patients on the effective use of their inhalers, utilizing advanced object recognition and movement interpretation technologies. This innovative approach aims to improve patient adherence to inhalation therapy, ultimately reducing hospital visits and lowering overall therapy costs for chronic lung conditions.

ChemiCare is a biotech company founded in 2016 that focuses on discovering and developing therapies for calcium-related rare genetic diseases. It aims to restore normal intracellular calcium levels by modulating store-operated calcium entry with drug-like modulators, crafted through click chemistry to enable exploration of chemical space and rapid refinement of candidate compounds, thereby accelerating drug discovery and development.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

VSPARTICLE is a company that specializes in the development of nanoparticle generators, facilitating the on-site production of microscopic particles for various applications, including sensors, batteries, catalysis, solar cells, healthcare, and additive manufacturing. Founded in 2014 and headquartered in Delft, The Netherlands, VSPARTICLE enables researchers and industry professionals to create new materials with ease, allowing for faster development and integration into final products. The company's technology emphasizes sustainable and flexible production methods, providing essential building blocks for innovative applications across multiple sectors. By streamlining the production process, VSPARTICLE supports the advancement of materials science and contributes to the creation of environmentally friendly technologies.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

E-Motion Medical Ltd was founded in 2011 by a pioneering multidisciplinary team with extensive experience in medicine, science, management and business. The E-Motion System™ delivers unique patterns of stimulation to the esophagus, thereby generating contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract. The stimulation is applied to the esophagus using their proprietary E-Motion Tube™, which can also double as a feeding tube, and is easily placed in the same manner.

CMI NOV SAS is a French healthcare company that specializes in designing, developing, and manufacturing medical devices for surgical applications. Founded in 2013 and based in Monistrol sur Loire, the company focuses on various medical fields, including cardiology, visceral surgery, gynecology, urology, and bariatrics. Notably, CMI NOV offers innovative solutions for mitral valve repair during open heart surgery, contributing to advancements in cardiac care. The company's commitment to enhancing surgical practices positions it as a key player in the medical device industry.

Founded in London in 2017, Limbic specializes in developing software solutions for mental health. They create AI-driven agents to assist in patient intake, triage, screening, and therapy, aiming to enhance the efficiency of healthcare providers and improve patient outcomes.

MyoSwiss is a Swiss medtech company that develops robotic and textile technology to help people with muscle weakness regain mobility and independence. The company manufactures the Myosuit and Myofit training devices used in rehabilitation and physiotherapy to improve walking and running ability. It offers individualized training plans, intensive and activity-based training, and performance tracking, along with a multifunctional training device that provides an additional layer of muscle support for mobility-impaired patients. Founded in 2017, the company is based in Zurich, Switzerland.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Radiobotics is a technology company focused on developing advanced machine learning algorithms that assist healthcare professionals in analyzing medical images, particularly x-rays of bones and joints. By automating routine tasks and generating radiology reports, the company's solutions facilitate quicker access to critical diagnostic information, thereby enhancing the quality of medical decision-making. Radiobotics aims to support doctors by streamlining the image analysis process, ultimately contributing to improved patient outcomes through more accurate and timely diagnoses.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

Capitainer is a Swedish medical device company that develops volumetric blood collection devices for fixed-volume dried blood spots collected at home. The device enables patients to remotely collect a predefined blood volume, which can be mailed to a laboratory for analysis. The technology aims to reduce patient travel and healthcare resources required for blood sampling, while delivering improved accuracy over conventional methods and offering cost and environmental savings for healthcare providers handling large volumes of samples. Founded in 2016 and based in Stockholm, Capitainer focuses on enabling convenient, safe, and reliable remote blood collection for quantitative testing.

Natac is a company that researches, develops, and sustainably manufactures natural plant extracts and ingredients from botanical origins, along with omega-3 from fish, for nutraceutical, pharmaceutical, food, animal nutrition, and cosmetic industries. It delivers premium, value-added bioactive compounds derived from botanicals, with plant sources certified through HABOID, a proprietary analytical method ensuring purity. Sustainability is integral to Natac’s operations; it analyzes agricultural processes to identify interventions that reduce environmental impact and aims to use the whole plant. The company maintains international reach, with manufacturing, research and development, innovation, and quality functions based in Spain to meet European standards. Natac markets natural ingredients from botanicals and fish, organized into vegetable extracts and omega-3 segments, with vegetable extracts accounting for the majority of revenue.

WearHealth specializes in workplace safety intelligence. It offers wearable sensors that use AI-driven ergonomics to prevent injuries in real-time. The platform provides posture correction alerts, risk assessment data, and tools to enhance worker safety and operational efficiency across industries like warehousing, logistics, manufacturing, construction, and mining.

liberDi is an Israeli company that specializes in developing portable automatic peritoneal dialysis systems for patients with end-stage renal disease. The company has created a comprehensive Digital Dialysis Clinic that enables patients to manage their own dialysis care with the assistance of an Intelligent Dialysis Assistant and remote medical supervision. This innovative self-care system allows patients to perform dialysis conveniently from various locations, such as their homes or while traveling, thereby enhancing their quality of life. Founded in 2014, liberDi aims to transform the traditional dialysis model by providing a safe, patient-friendly alternative to in-clinic care. The company's technology not only empowers patients but also helps clinics optimize their operations, improve service quality, and reduce costs, establishing a holistic platform for renal patients and their caregivers.

OnDosis is a Swedish company founded in 2017, focusing on personalized medicine through its innovative dosing technology. The company specializes in delivering flexible and individualized dosing of oral medications, which are formulated as micro units like pellets, granules, mini tablets, or powders. By integrating digital technologies with traditional drug-based treatments, OnDosis aims to enhance disease management and improve patient adherence, particularly for conditions such as ADHD, pain management, and immunosuppression in organ transplant recipients. Their approach addresses the limitations of conventional tablets or capsules, providing greater convenience and improved health outcomes for patients. The technology developed by OnDosis is rooted in research from AstraZeneca and is supported by a network of strategic partners that assist in various core functions, including formulation, device development, and regulatory compliance.

EmeraMed Limited is a privately held biotechnology company based in the Republic of Ireland, with operations in Ireland, Sweden, and the United States. The company's ownership group consists mainly of physicians, dentists, and patients who have previously used its products as dietary supplements. EmeraMed is focused on developing a lipophilic antioxidant capable of penetrating the blood-brain barrier. The company's primary goal is to chelate free iron and various heavy metals, including mercury and lead, which can generate harmful free radicals. By addressing these issues, EmeraMed aims to help healthcare providers restore normal mitochondrial function and enhance overall health.

Revamp Medical, founded in 2016, is dedicated to addressing the critical unmet needs of patients suffering from acute heart failure. With over one million annual admissions in the United States and associated costs exceeding $65 billion, the company aims to provide an innovative solution through its patented temporary catheter, Doraya™. This device regulates vascular hemodynamics, particularly for patients experiencing diuretic resistance, by managing preload and reducing central venous pressure. This functionality enhances diuretic efficacy and facilitates progressive decongestion, thereby allowing cardiologists to effectively manage key hemodynamic parameters. Revamp Medical is supported by a skilled team with extensive experience in the medical technology sector, positioning the company to make a significant impact in the treatment of acute heart failure.

Aspivix develops innovative medical devices aimed at enhancing safety and comfort in gynecological procedures. Its flagship product, CAREVIX, employs suction technology to gently stabilize the cervix during procedures, reducing pain and minimizing risks such as bleeding and infections.

Somax Systems specializes in developing and marketing advanced ultrasound imaging devices tailored for healthcare professionals. Their flagship product is a compact, versatile scanner poised to become an indispensable tool akin to current staples like stethoscopes or thermometers. The company's core values include trust, innovation, quality, and sustainability, guiding their pursuit of superior imaging solutions that meet evolving healthcare needs.

eLive Ecosystem specializes in developing innovative solutions aimed at preventing long-term diseases through advanced technology. The company has created an artificial intelligence-based medical device specifically designed for the self-measurement of sleep apnea, addressing diagnostic gaps and enhancing treatment monitoring. By integrating medicine, genomics, and advanced sensor technology, eLive aims to alleviate the pressures on healthcare systems caused by demographic changes and aging populations. Their platform focuses on enabling healthcare professionals to efficiently and cost-effectively manage disease prevention and treatment, ultimately improving patient outcomes on a global scale.

Stemcis is a medical device manufacturer based in Saint-Denis, France, specializing in the research and development of adipose tissue applications for both human and veterinary medicine. The company focuses on creating surgical kits designed for the collection, treatment, and re-injection of fat cell preparations. Through its innovative protocols and products, Stemcis aims to address various medical conditions by leveraging the therapeutic potential of adipose tissue. The company's expertise in tissue engineering plays a crucial role in advancing treatments for multiple pathologies.

Brainmarc Ltd. is a company that specializes in developing a digital platform for cognitive remediation, utilizing its proprietary Brain Engagement Index (BEI) technology. Founded in 2013 and headquartered in Yokne'am, Israel, with an additional office in Hoboken, New Jersey, Brainmarc's platform employs electroencephalography (EEG) sensors to monitor brain engagement and mental activity. The technology provides insights into patients' attention levels during cognitive exercises, offering a more accessible alternative to traditional multi-electrode EEG systems. Brainmarc's innovative approach has demonstrated significant efficacy in treating cognitive impairments, with its solutions validated through numerous patient cases in clinical settings across the United States, Canada, the European Union, and Israel. The company aims to enhance the understanding and management of cognitive and mental disorders through its therapeutic products.